Edwards Lifesciences (EW) Total Current Liabilities (2016 - 2025)
Edwards Lifesciences has reported Total Current Liabilities over the past 17 years, most recently at $1.8 billion for Q4 2025.
- Quarterly results put Total Current Liabilities at $1.8 billion for Q4 2025, up 20.5% from a year ago — trailing twelve months through Dec 2025 was $1.8 billion (up 20.5% YoY), and the annual figure for FY2025 was $1.8 billion, up 20.5%.
- Total Current Liabilities for Q4 2025 was $1.8 billion at Edwards Lifesciences, up from $1.6 billion in the prior quarter.
- Over the last five years, Total Current Liabilities for EW hit a ceiling of $1.9 billion in Q3 2024 and a floor of $799.0 million in Q1 2021.
- Median Total Current Liabilities over the past 5 years was $1.1 billion (2023), compared with a mean of $1.2 billion.
- Biggest five-year swings in Total Current Liabilities: surged 56.92% in 2024 and later decreased 18.32% in 2025.
- Edwards Lifesciences' Total Current Liabilities stood at $1.0 billion in 2021, then dropped by 0.96% to $1.0 billion in 2022, then rose by 16.92% to $1.2 billion in 2023, then increased by 25.92% to $1.5 billion in 2024, then grew by 20.5% to $1.8 billion in 2025.
- The last three reported values for Total Current Liabilities were $1.8 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.4 billion (Q2 2025) per Business Quant data.